哈莫尼生物科技

最新新闻

• 评级变动
  Piper Sandler Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Cuts Target Price to $46
  \u5e02\u573a\u8d44\u8baf · 2026/4/22
• 评级变动
  Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/4/14
• Wolfe Research Initiates Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• 评级变动
  Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $44
  \u5e02\u573a\u8d44\u8baf · 2026/2/24
• 评级变动
  A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $30 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $51
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $72
  \u5e02\u573a\u8d44\u8baf · 2026/4/22
• 评级变动
  Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $39
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $36
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $51
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)
  TipRanks · 2026/7/16
• 评级变动
  Goldman Sachs Upgrades Harmony Biosciences(HRMY.US) to Hold Rating, Raises Target Price to $37
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 评级变动
  A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $30 to $62
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  Truist Financial Maintains Harmony Biosciences(HRMY.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/2/24

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。